Stay updated on Nal-Irinotecan & Nivolumab in Biliary Cancer Clinical Trial

Sign up to get notified when there's something new on the Nal-Irinotecan & Nivolumab in Biliary Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nal-Irinotecan & Nivolumab in Biliary Cancer Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3 on the page.
    Difference
    0.1%
    Check dated 2026-03-12T20:40:03.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The two screenshots show no detectable differences in the page content. Study design, eligibility criteria, and outcome measures appear unchanged.
    Difference
    0.1%
    Check dated 2026-03-05T18:08:55.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    Added a Results Posted entry on 2026-02-13 detailing DLT incidence, PFS, adverse events, ORR/OS, and related time frames, and uploaded associated documents (Informed Consent Form, Protocol and SAP).
    Difference
    2%
    Check dated 2026-02-19T05:29:31.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2 and removed Revision: v3.4.1; these are minor site version updates and do not affect the study content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-12T02:30:51.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    Site revision updated from v3.4.0 to v3.4.1, a minor update that does not affect study content or page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-04T23:54:19.000Z thumbnail image
  7. Check
    48 days ago
    Change Detected
    Summary
    Added a glossary display and updated metadata labels 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and 'Revision: v3.4.0', while removing the lowercase/older labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4'. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-28T20:06:12.000Z thumbnail image

Stay in the know with updates to Nal-Irinotecan & Nivolumab in Biliary Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nal-Irinotecan & Nivolumab in Biliary Cancer Clinical Trial page.